美普地尔 | 23891-60-3

• 物质功能分类: 原料药 - 循环系统用药 - 防治心绞痛药
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 美普地尔
• 英文名称: 3-(3,3-diphenylpropylamino)propyl 3,4,5-trimethoxybenzoate
• 英文别名: Mepramidil
• CAS: 23891-60-3
• 化学式: C₂₈H₃₃NO₅
• 分子量: 463.574
• InChiKey: IFYJCDHOWBSELI-UHFFFAOYSA-N

物化性质

• 沸点：
  573.5±49.0 °C(Predicted)
• 密度：
  1.116±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.4
• 重原子数：
  34
• 可旋转键数：
  14
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  66
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2922509090

文献信息

• Diagnostic/therapeutic agents
  申请人：Klaveness Jo

  公开号：US20050002865A1

  公开（公告）日：2005-01-06

  Targetable diagnostic and/or therapeutically active agents, e.g. ultrasound contrast agents, comprising a suspension in an aqueous carrier liquid of a reporter comprising gas-containing or gas-generating material, said agent being capable of forming at least two types of binding pairs with a target.

  可定位的诊断和/或治疗活性剂，例如超声对比剂，包括悬浮在水载体液中的报告物，该报告物包含含气体或生成气体的材料，该剂能够与目标形成至少两种结合对。
• Liposomal human calcitonin gene-related peptide composition and preparation of the same
  申请人：Wo, Weihan

  公开号：EP0845269A2

  公开（公告）日：1998-06-03

  The present invention provides a pharmaceutical composition of hCGRP and the preparation of the same. The composition comprises liposomes from natural soybean phospholipid, in which the weight ratio of hCGRP to soybean phospholipid is 1-2 to 100-8000. The half-life of the composition is longer than 72 hours, and the stability of the composition is also elongated. The composition can be administrated by intravenous infusion, oral, nasal mucosal spray in an amount of 0.1-10 pg hCGRP per kg body weigh to treat hypertension and congestive heart failure of a human. The bioavailability of approximately 80%.

  本发明提供了一种 hCGRP 的药物组合物及其制备方法。该组合物由天然大豆磷脂制成的脂质体组成，其中 hCGRP 与大豆磷脂的重量比为 1-2 比 100-8000。该组合物的半衰期超过 72 小时，稳定性也更长。该组合物可以通过静脉注射、口服、鼻黏膜喷雾等方式给药，剂量为每千克体重 0.1-10 pg hCGRP，用于治疗人类的高血压和充血性心力衰竭。生物利用率约为 80%。
• Yeast strain and method for producing natural cinnamic acid using the yeast strain for fermentation
  申请人：XIAMEN OAMIC BIOTECHNOLOGY CO., LTD.

  公开号：US10392672B2

  公开（公告）日：2019-08-27

  The present invention relates to a strain of Rhodotorula sp. OMK-1(CCTCC M 2015326) and a method for producing natural cinnamic acid through the fermentation of Rhodotorula sp. OMK-1. The production method comprises steps of strain activation, seed culture, fermentation, extraction, etc. The fermentation process uses natural glucose, amino acids, etc. as raw materials to produce cinnamic acid via the metabolism of Rhodotorula sp. OMK-1. The present invention provides a safe and environmentally friendly method for producing natural cinnamic acid at low temperature and low pressure with simple operation and reduced pollution.

  本发明涉及一种Rhodotorula sp.OMK-1(CCTCC M 2015326)菌株和一种通过发酵Rhodotorula sp.OMK-1生产天然肉桂酸的方法。该生产方法包括菌种活化、种子培养、发酵、提取等步骤。发酵过程以天然葡萄糖、氨基酸等为原料，通过根瘤菌 OMK-1 的新陈代谢生产肉桂酸。本发明提供了一种安全环保的低温低压生产天然肉桂酸的方法，操作简单，减少污染。
• Controlled absorption water-soluble pharmaceutically active organic compound formulation for once-daily administration
  申请人：Counts David F.

  公开号：US10463611B2

  公开（公告）日：2019-11-05

  The present disclosure provides a once-daily water-soluble pharmaceutically active formulation for oral administration. In certain embodiments, the composition comprises a water-soluble pharmaceutically active organic compound incorporated into a small particulate, each particulate having a core of the water-soluble pharmaceutically active organic compound or an acceptable salt thereof in reversible association with a pharmaceutically acceptable drug-binding polymer. The core of the composition being surrounded by an insoluble water permeable membrane that is capable of delaying the dissolution of the pharmaceutically active compound therewithin and providing for extended release of the pharmaceutically active compound. In some embodiments, the formulation of the invention are designed to extend release of the pharmaceutically active organic compound for about 3 hours to about 8 hours, thereby enabling preparation of an extended release formulation for any pharmaceutically active compound with a half-life of from about 16 hours to about 21 hours.

  本公开提供了一种用于口服的每日一次水溶性药用活性制剂。在某些实施方案中，该组合物包括掺入小颗粒中的水溶性药用活性有机化合物，每个颗粒都有一个水溶性药用活性有机化合物或其可接受盐的核心，该核心与药学上可接受的药物结合聚合物可逆结合。组合物的核心由不溶性透水膜包围，该膜能够延迟其中的药用活性化合物的溶解，并延长药用活性化合物的释放时间。在某些实施方案中，本发明的制剂可将药用活性有机化合物的释放时间延长约 3 小时至约 8 小时，从而能够制备半衰期为约 16 小时至约 21 小时的任何药用活性化合物的缓释制剂。
• LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY
  申请人：Scidose, Llc

  公开号：EP1954244A1

  公开（公告）日：2008-08-13